Medical condition
Weight Loss
Weight Loss is a medical condition tracked by NovaPharmaNews across 5 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- tirzepatide (MOUNJARO) Alimentary tract and metabolism (A10)
- semaglutide (OZEMPIC) Alimentary tract and metabolism (A10)
- orlistat (XENICAL) Alimentary tract and metabolism (A08)
- anamorelin (ADLUMIZ) Various (V03)
- interferon alfa-2b (INTRONA) Antineoplastic and immunomodulating agents (L03)
Latest Weight Loss news
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Amgen’s MariTide phase 2 obesity data showed up to 20% average weight loss at 52 weeks in participants without type 2 diabetes. The trial also reported up to 17% average weight loss in participants with type 2 diabetes, with placebo results provided in the published data.
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Amgen’s MariTide Phase 2 obesity study reported up to ~20% average weight loss at one year in participants without type 2 diabetes and up to ~17% in those with type 2 diabetes. The plan below focuses only on the trial facts, the placebo comparisons, and the clinical-trial readouts already supported by source material.
14 New Weight Loss Drugs: Regulatory Updates and Implications
This article tracks the latest regulatory updates on 14 new weight loss drugs, focusing on implications for pharmaceutical teams and investors. Key insights on FDA processes included.
FDA Restricts Large-Scale Compounding of Weight Loss Drugs
On May 4, 2026, the FDA announced restrictions on large-scale compounding of three weight loss drugs, signaling significant changes in the pharmaceutical landscape. This move has implications for investors and pharmaceutical teams alike.
Eli Lilly’s Triple-G Drug Achieves Bariatric Surgery-Level Weight Loss
Eli Lilly's 'triple-G' drug demonstrates impressive weight loss results in clinical trials, raising competitive stakes in the obesity treatment market.
Zealand Pharma's Survodutide Achieves 16.6% Weight Loss in Phase 3 Obesity Trial, Outperforming Current GLP-1 Therapies
Zealand Pharma announces survodutide achieved 16.6% weight loss in Phase 3 SYNCHRONIZE-1 trial, potentially exceeding Wegovy and Zepbound efficacy rates.
FDA Approves Higher-Dose Wegovy 7.2mg for Weight Loss Under Priority Review Program
Novo Nordisk's Wegovy receives FDA approval for 7.2mg dose under National Priority Voucher Program, expanding treatment options for adult obesity patients.